Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT00820768 Withdrawn - Solid Tumor Clinical Trials

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Start date: April 1, 2012
Phase: Phase 1
Study type: Interventional

To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.

NCT ID: NCT00808184 Completed - Solid Tumor Clinical Trials

Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The objectives of this study are: To correlate pharmacokinetic parameters of raltegravir and midazolam with irinotecan (CPT-11) and its metabolite SN-38. To correlate the genotype of UGT1A1 of patients receiving CPT-11 chemotherapy with irinotecan and raltegravir pharmacokinetic parameters. To model pharmacokinetic and pharmacodynamic behaviour of CPT-11 in the study population.

NCT ID: NCT00803556 Completed - Breast Cancer Clinical Trials

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Start date: January 2006
Phase: Phase 1
Study type: Interventional

To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies

NCT ID: NCT00786838 Completed - Solid Tumor Clinical Trials

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in participants with advanced solid tumor malignancies when administered at a therapeutic dose.

NCT ID: NCT00786669 Completed - Solid Tumor Clinical Trials

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

VITAC
Start date: October 2008
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety and of adding bevacizumab to the established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what effects it has in pediatric patients with relapsed or refractory solid tumors.

NCT ID: NCT00781846 Completed - Solid Tumor Clinical Trials

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose of oral ridaforolimus administered in combination with intravenous bevacizumab in patients with advanced cancers.

NCT ID: NCT00753740 Withdrawn - Cancer Clinical Trials

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.

NCT ID: NCT00742105 Terminated - Cancer Clinical Trials

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Start date: November 17, 2008
Phase: Phase 1
Study type: Interventional

This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.

NCT ID: NCT00737555 Completed - Solid Tumor Clinical Trials

A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the investigational drug CHR-2797 (given orally, once daily). The purpose of this study is to evaluate if it is safe to administer these two drugs together, and how well the combination is tolerated by patients. The first patients will receive a 90mg dose of CHR-2797; doses will be increased in subsequent patients, as long as they are adequately tolerated.

NCT ID: NCT00736749 Recruiting - Leukemia Clinical Trials

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Start date: July 17, 2008
Phase:
Study type: Observational

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.